Table 5.
Treatment response of different DAA regimens from 2018 to 2021.
| Duration | DAA regimens | Response rate (CHC) | Response rate (LC) |
|---|---|---|---|
| 2017–2019 | OBV/PTV/r/DSV | 100% (92/92) | 97.22% (35/36) |
| SOF + RBV | 100% (41/41) | 85.19% (23/27) | |
| EBR/GZR | 100% (45/45) | 100% (17/17) | |
| SOF + DCV ± RBV | 100% (8/8) | 100% (20/20) | |
| ASV + DCV | 100% (2/2) | 100% (3/3) | |
| GLE/PIB | 100% (4/4) | 100% (1/1) | |
|
| |||
| 2020–2021 | SOF/vel ± rbv | 100% (27/27) | 100% (41/41) |
| SOF/ldv ± rbv | 100% (19/19) | 100% (20/20) | |
DAA, directing antiviral agents; CHC, chronic hepatitis C; LC, liver cirrhosis; OBV/PTV/r, ombitasvir/paritaprevir/ritonavir; DSV, dasabuvir; SOF, sofosbuvir; RBV, ribavirin; EBR/GZR, elbasvir/grazoprevir; DCV, daclatasvir; ASV, asunaprevir; GLE/PIB: glecaprevir/pibrentasvir; VEL, velpatasvir; LDV, ledipasvir.